Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamoru Harada

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 24, 2016
[Chemotherapy and Anticancer Immune Responses]Mamoru Harada
Journal for Immunotherapy of Cancer|December 13, 2024
Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103<sup>+</sup> IL-12-producing dendritic cells and priming CD8<sup>+</sup> T cells without involving draining lymph nodesYuichi Iida, Mamoru Harada
International Journal of Clinical Oncology|September 5, 2003
Target molecules in specific immunotherapy against prostate cancerMamoru Harada, Masanori Noguchi, Kyogo Itoh
Molecular Cancer|September 18, 2014
Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A systemNanae Harashima, Takafumi Minami, Hirotsugu Uemura, et al.
Microbiology and Immunology|November 15, 2023
Modulatory effects of supplementation of Lentinula edodes mycelia extract and  l-arginine on the therapeutic efficacy of immunogenic chemotherapy in colon cancer-bearing miceTakahito Taniura, Kazunari Ishitobi, Masaaki Hidaka, et al.
Oncotarget|October 28, 2015
Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAILYoko Hari, Nanae Harashima, Yoshitsugu Tajima, et al.
Oncology Reports|February 3, 2007
Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patientsMamoru Harada, Yuki Ishihara, Kyogo Itoh, et al.
International Journal of Oncology|April 16, 2016
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cellsTakeharu Ogura, Yoshiyuki Tanaka, Hiroki Tamaki, et al.
Oncotarget|May 6, 2017
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expressionNanae Harashima, Keizo Takenaga, Miho Akimoto, et al.
Cancer Science|July 5, 2003
Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patientsKazuhiko Kobayashi, Masanori Noguchi, Kyogo Itoh, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 24, 2016
[Chemotherapy and Anticancer Immune Responses]Mamoru Harada
Journal for Immunotherapy of Cancer|December 13, 2024
Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103<sup>+</sup> IL-12-producing dendritic cells and priming CD8<sup>+</sup> T cells without involving draining lymph nodesYuichi Iida, Mamoru Harada
International Journal of Clinical Oncology|September 5, 2003
Target molecules in specific immunotherapy against prostate cancerMamoru Harada, Masanori Noguchi, Kyogo Itoh
Molecular Cancer|September 18, 2014
Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A systemNanae Harashima, Takafumi Minami, Hirotsugu Uemura, et al.
Microbiology and Immunology|November 15, 2023
Modulatory effects of supplementation of Lentinula edodes mycelia extract and  l-arginine on the therapeutic efficacy of immunogenic chemotherapy in colon cancer-bearing miceTakahito Taniura, Kazunari Ishitobi, Masaaki Hidaka, et al.
Oncotarget|October 28, 2015
Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAILYoko Hari, Nanae Harashima, Yoshitsugu Tajima, et al.
Oncology Reports|February 3, 2007
Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patientsMamoru Harada, Yuki Ishihara, Kyogo Itoh, et al.
International Journal of Oncology|April 16, 2016
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cellsTakeharu Ogura, Yoshiyuki Tanaka, Hiroki Tamaki, et al.
Oncotarget|May 6, 2017
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expressionNanae Harashima, Keizo Takenaga, Miho Akimoto, et al.
Cancer Science|July 5, 2003
Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patientsKazuhiko Kobayashi, Masanori Noguchi, Kyogo Itoh, et al.
Pageof 11